公开(公告)号：US11576970B2

公开(公告)日：2023-02-14

申请号：US16083321

申请日：2017-03-09

Applicant: UCB BIOPHARMA SPRL

Inventor： Andrew Jeffrey Yates ,  James Gregory Clipstone

IPC: A61K39/395 ,  C07K16/22 ,  A61K9/00 ,  A61K47/18 ,  A61K9/08 ,  A61K47/20 ,  A61K47/40 ,  A61K39/00

Abstract: The invention relates to a liquid pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof, cyclodextrin and methionine. In addition, it relates to a method for reducing precipitation of an antibody or an antigen-binding fragment thereof in a liquid pharmaceutical formulation through addition of methionine and cyclodextrin. In particular, the liquid pharmaceutical formulations comprises an anti-sclerostin antibody, hydroxypropyl-gamma cyclodextrin and methionine and may be used in the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength, and especially for treating osteoporosis. Furthermore, the invention relates to a method of reducing inflammation at injection site in a mammalian subject comprising administering a therapeutically effective amount of a liquid pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof, cyclodextrin and methionine.

公开(公告)号：US11466324B2

公开(公告)日：2022-10-11

申请号：US16248219

申请日：2019-01-15

Applicant: UCB BIOPHARMA SPRL

Inventor： Adam Samuel Platt ,  Stephen Edward Rapecki ,  Mara Fortunato ,  David Robert Rainey ,  Jon Leigh Rundle ,  Paul Alfred Smith ,  Gillian Fairfull Watt

IPC: G01N33/68 ,  C12Q1/6883 ,  C12Q1/6886

Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.

公开(公告)号：US11384136B2

公开(公告)日：2022-07-12

申请号：US16674003

申请日：2019-11-05

Applicant: UCB BIOPHARMA SPRL

Inventor： Jean-Pascal Pierre Bilgischer ,  Philip Jonathan Bassett ,  Mark Robert Pearce-Higgins ,  Andrew John Kenny

IPC: C07K16/00 ,  C12P21/00

Abstract: The present disclosure relates to a method for the manufacture of recombinant antibody molecules comprising culturing a host cell sample transformed with an expression vector encoding a recombinant antibody molecule; adding an extraction buffer to the sample; and subjecting the sample to a heat treatment step; wherein the pH of the sample is detected after addition of the extraction buffer, and optionally adjusted, to ensure that the pH of the sample is 6 to 9 prior to the heat treatment step.

公开(公告)号：US11286312B2

公开(公告)日：2022-03-29

申请号：US15779417

申请日：2016-12-01

Applicant: UCB BIOPHARMA SPRL

Inventor： Pallavi Bhatta ,  Laura Starkie ,  Michael John Wright

IPC: C07K16/46 ,  C07K16/14 ,  C07K14/395 ,  C07K16/00 ,  C12N15/10

Abstract: The present invention relates to heterodimerically-tethered bispecific protein complexes (according to the general formula of A-X:Y-B) and libraries/multiplexes thereof for use in research and therapy and in particular an in vitro/ex vivo method of detecting synergistic biological function of otherwise unknown pairs of targets.

公开(公告)号：US11059820B2

公开(公告)日：2021-07-13

申请号：US16615992

申请日：2018-05-24

Applicant: UCB BIOPHARMA SPRL

Inventor： Luc Lambert Jozef Jan Aerts ,  Georges Assaf ,  Nicolas Edmond Carly ,  Vincent Adolphe Carol Cool ,  Jean-Pierre Delatinne ,  Laurent Jacques Willy Delhaye ,  Jean Paul Kestemont ,  Sarah Le Meur

IPC: C07D471/04 ,  A61K31/519 ,  A61P3/00 ,  A61P9/00

Abstract: Crystalline forms of seletalisib, designated as Form B and Form F and characterized herein, being selective inhibitors of PI3 kinase enzymes, in particular of the human PBKδ isoform, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

公开(公告)号：US10774152B2

公开(公告)日：2020-09-15

申请号：US15326499

申请日：2015-07-16

Applicant: UCB BIOPHARMA SPRL

Inventor： Helene Margaret Finney ,  Stephen Edward Rapecki ,  Michael John Wright ,  Kerry Louise Tyson

IPC: A61K39/00 ,  C07K16/28 ,  C07K16/18 ,  C07K16/46

Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.

公开(公告)号：US10358493B2

公开(公告)日：2019-07-23

申请号：US15311198

申请日：2015-05-28

Applicant: UCB BIOPHARMA SPRL

Inventor： Helene Margaret Finney ,  Stephen Edward Rapecki ,  Michael John Wright

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/14 ,  C07K16/46 ,  G01N33/68

Abstract: The present disclosure relates to a novel bispecific protein complex and a method of using the complexes to screen for synergistic or novel biological function. The bispecific format is particularly suitable for high-throughput screening because all of its components can be expressed from cells as individual units and the units can be assembled simply by mixing without employing conjugation or coupling chemistry.

公开(公告)号：US10316097B2

公开(公告)日：2019-06-11

申请号：US15577035

申请日：2016-05-25

Applicant: UCB BIOPHARMA SPRL

Inventor： Patrice Marie Charles Godard ,  Rafal Marian Kaminski ,  Karine Josee Jeanne Leclercq ,  Jonathan Marie M Van Eyll

IPC: G01N33/53 ,  A61K39/395 ,  C07K14/475 ,  C07K14/48 ,  A61K38/00 ,  A61K38/18 ,  A61K49/00 ,  A61K49/16 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K38/17 ,  C07K14/47 ,  C07K16/28 ,  A61P25/28 ,  A61P25/18 ,  A61P25/16 ,  A61K39/00

Abstract: The present invention pertain an inhibitor of CSF-1R activity for use in the treatment and/or prophylaxis of neurologic diseases and new method of treatment of neurologic diseases.

公开(公告)号：US10308723B2

公开(公告)日：2019-06-04

申请号：US15482260

申请日：2017-04-07

Applicant: UCB BIOPHARMA SPRL

Inventor： Ralph Adams ,  Andrew George Popplewell ,  Stephen Edward Rapecki

IPC: A61K39/395 ,  C07K16/46 ,  C07K16/24

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

公开(公告)号：US10093652B2

公开(公告)日：2018-10-09

申请号：US15038287

申请日：2014-12-08

Applicant: UCB Biopharma SPRL

Inventor： Jag Paul Heer ,  Victoria Elizabeth Jackson ,  Boris Kroeplien ,  Fabien Claude Lecomte ,  John Robert Porter

IPC: A61K35/28 ,  A01N1/02 ,  G01N33/569 ,  C12N5/0789 ,  C07D401/10 ,  C07D235/12 ,  A61K31/4439

Abstract: A series of substituted 4,5,6,7-tetrahydrobenzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.